2. Search Result
Search Result
Results for "

SNI

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-76772
    Cevimeline hydrochloride hemihydrate
    2 Publications Verification

    SNI-2011; AF102B hydrochloride hemihydrate

    		 mAChR Neurological Disease Cancer
    Cevimeline hydrochloride hemihydrate (SNI-2011) is a quinuclidine derivative of acetylcholine and a selective and orally active muscarinic M1 and M3 receptor agonist. Cevimeline hydrochloride hemihydrate stimulates secretion by the salivary glands and can be used as a sialogogue for xerostomia . Cevimeline hydrochloride hemihydrate can cross the blood-brain barrier (BBB) .
    Cevimeline hydrochloride hemihydrate
  • HY-W044764
    2-Benzylsuccinic acid
    1 Publications Verification

    DL-Benzylsuccinic acid

    		 Carboxypeptidase Neurological Disease Metabolic Disease
    2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis .
    2-Benzylsuccinic acid
  • HY-117731
    UKH-1114

    		Sigma Receptor Neurological Disease
    UKH-1114 is a selective TMEM97 (a sigma-2 receptor) agonist with a Ki values of 1279 and 46 nM for σ1R and σ2R/TMEM97, respectively. UKH-1114 exhibits exceptional selectivity with negligible affinity for over 50 other receptors and channels. UKH-1114 effectively relieves spared nerve injury (SNI)-induced mechanical hypersensitivity with a long-lasting duration and without motor impairment. UKH-1114 can be used for neuropathic pain research .
    UKH-1114
  • HY-159972
    PKR1 antagonist 1

    		Prokineticin Receptor Neurological Disease
    PKR1 antagonist 1 (PC1) is a potent PKR1 antagonist. PKR1 antagonist 1 reduces hyperalgesia and allodynia in SNI mice .
    PKR1 antagonist 1
  • HY-76772B
    (-)-Cevimeline hydrochloride hemihydrate

    (-)-SNI-2011; (-)-AF102B hydrochloride hemihydrate

    		 mAChR Neurological Disease
    (-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.
    (-)-Cevimeline hydrochloride hemihydrate
  • HY-76772A
    (+)-Cevimeline hydrochloride hemihydrate

    (+)-SNI-2011; (+)-AF102B hydrochloride hemihydrate

    		 mAChR Neurological Disease
    (+)-Cevimeline hydrochloride hemihydrate ((+)-SNI-2011), a potent muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.
    (+)-Cevimeline hydrochloride hemihydrate
  • HY-W044764R
    2-Benzylsuccinic acid (Standard)

    		Reference Standards Carboxypeptidase Neurological Disease Metabolic Disease
    2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis .
    2-Benzylsuccinic acid (Standard)
  • HY-162347
    Nav1.7-IN-13

    		Sodium Channel Neurological Disease
    Nav1.7-IN-13 (compound 3g) is a sodium channel inhibitor that significantly inhibits Veratridine (HY-N6691)-induced neuronal activity. Nav1.7-IN-13 inhibits total Na+ current in DRG neurons in a concentration-dependent manner; slows down the activation of Navs. Nav1.7-IN-13 significantly alleviated mechanical pain behavior in a rat model of nerve injury (SNI) and had analgesic activity .
    Nav1.7-IN-13
  • HY-163207
    sEH/HDAC6-IN-1

    		Epoxide Hydrolase HDAC Neurological Disease
    sEH/HDAC6-IN-1 (compound M9) is a selective, orally active dual inhibitor for sEH and HDAC6, with IC50s of 2 nM, 0.72 nM and 5 nM, for human sEH, murine sEH and HDAC6, respectively. sEH/HDAC6-IN-1 reveals analgesic and anti-inflammatory effects .
    sEH/HDAC6-IN-1
  • HY-76772R
    Cevimeline hydrochloride hemihydrate (Standard)

    SNI-2011 (Standard); AF102B hydrochloride hemihydrate (Standard)

    		 mAChR Reference Standards Neurological Disease Cancer
    Cevimeline (hydrochloride hemihydrate) (Standard) is the analytical standard of Cevimeline (hydrochloride hemihydrate). This product is intended for research and analytical applications. Cevimeline hydrochloride hemihydrate (SNI-2011) is a quinuclidine derivative of acetylcholine and a selective and orally active muscarinic M1 and M3 receptor agonist. Cevimeline hydrochloride hemihydrate stimulates secretion by the salivary glands and can be used as a sialogogue for xerostomia . Cevimeline hydrochloride hemihydrate can cross the blood-brain barrier (BBB) .
    Cevimeline hydrochloride hemihydrate (Standard)
  • HY-182940
    SARM1-IN-10

    		Toll-like Receptor (TLR) Neurological Disease
    SARM1-IN-10 is an orally active SARM1 inhibitor with a pIC50 of 7.1 and a pKd of 8.3. As a base-exchange inhibitor, SARM1-IN-10 forms a NAD + adduct at the active site of the TIR domain of SARM1, blocks enzymatic function, and induces a unique rotameric state of W662 at the catalytic site of SARM1. SARM1-IN-10 acts as a paradoxical neurodegeneration inducer at low doses and an inhibitor at high doses, and it can exacerbate or protect against SARM1-mediated neurodegeneration depending on concentration. SARM1-IN-10 can be used in studies of peripheral neurodegeneration .
    SARM1-IN-10

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: